培美曲塞治疗45例复治晚期非小细胞肺癌的临床观察

Clinical Efficiency of Pemetrexed in the Treatment of 45 Patients with Advanced Retreated Non-small Cell Lung Cancer

目的观察培美曲塞单药(或联合顺铂)治疗复治晚期的非小细胞肺癌的临床疗效、临床获益率和毒副反应.方法病理确诊45例复治晚期的非小细胞肺癌患者接受培美曲塞500 mg/m2化疗,或联合顺铂25mg/m221 d为1个周期,重复直至疾病进展或出现不可耐受的毒副作用.结果总有效率(CR+PR)为31.11%,临床获益率(CR+PR+SD)为62.22%.主要毒副反应为骨髓抑制和胃肠反应.结论培美曲塞治疗晚期复治的非小细胞肺癌取得较明显的临床获益率,且毒副反应可耐受.

Obiective Pemetrexed is a multitargeted anti-metabolite. Pemetrexed has been approved as the second-line treatment in non-small cell lung cancer. Our aim was to evaluate the clinical efficiency, the clinical benefit response rate and toxicity of pemetrexed （combined with cisplatin） in treatment of advanced retreated non-small cell lung cancer. Methods 45 advanced retreated NSCLC patients received pemetrexed at a dose of 500 mg/m2, or combined with cisplatin at a dose of 25rag/m2, the chemotherapy was repeated every 21 days until disease progression or the occurrence of untolerant adverse reactions. Results The overall response rate was 31.11% , the clinical benefit rate was 62.22% , and the main toxic and adverse reactions were hematological toxicties and gastrointestinal reactions. Conclusion Pemetrexed is effective in treatment of advanced retreated non-small lung cancer and the toxicity can be well tolerated.